PosterSessionOnline

INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTA..

ISTH 2023 Congress

June, 24-28 Montreal

N. Poster

Poster title

Applicant name

Status


PB-0001	Force balance ratio is a robust predictor of arterial thrombus embolization	Dmitry Nechipurenko	Received

PB-0004	A Case of Bivalirudin Associated Diffuse Alveolar Hemorrhage following Percutaneous Coronary Intervention	Tania Ahuja	Received

PB-0010	Neutrophil-activating peptide 2 as a novel modulator of fibrin clot properties in patients with atrial fibrillation on anticoagulation	Magdalena Kopytek	Received

PB-0011	Evaluation of the association between clinical events and apixaban/rivaroxabans plasma exposure in patients from the OptimAT study	Jean-Luc Reny	Received

PB-0015	Potential of Racial Bias in Atrial Fibrillation Patients That are Switched from Warfarin to a Direct Oral Anticoagulant	Scott Kaatz	Received

PB-0016	Plasma protein carbonylation is associated with unfavorably altered fibrin clot properties in patients with atrial fibrillation: a novel risk factor of ischemic cerebrovascular events	Anetta Undas	Received

PB-0018	Direct oral anticoagulant plasma levels in patients with low body weight: a retrospective study	Anne-Laure Sennesael	Received

PB-0022	Impact of COVID-19 on thromboembolic events and mortality among patients with non-valvular atrial fibrillation receiving oral anticoagulants	Kristin Kistler	Received

PB-0024	LEFT ATRIAL APPENDAGE CLOSURE (LAAC) AS AN ALTERNATIVE TO ORAL ANTICOAGULATION (OACs) IN PATIENTS WITH ATRIAL FIBRILLATION (AF): A SINGLE CENTRE EXPERIENCE.	Gloria Garcia-Donas	Received

PB-0036	Plasma protein carbonyl levels contribute to prothrombotic fibrin clot phenotype in acute ischemic stroke patients: associations with clinical outcomes	Anetta Undas	Received

PB-0044	Pediatric arterial thrombosis: patient characteristics and thrombosis outcomes	Eman Abdelghani	Received

PB-50	Heparin concentrations in pediatric patients with Paediatric Inflammatory Multisystem Syndrome associated with COVID-19. The measurement importance in the inflammatory state.	Mara Nuñez Toscano	Received

PB-0051	Persistent elevation of ? fibrinogen in acute and convalescent COVID-19	Helen Fogarty	Received

PB-0055	Influence of argatroban on fibrinolysis ex-vivo in blood samples of healthy volunteers and in-vivo in critically ill COVID-19 patients	Mirjam Bachler	Received

PB-0065	Targeting the endothelium when treating convalescent COVID-19 patients, the effect on serum biomarkers, and post-COVID functional status. Midterm results of a randomized, placebo-controlled trial.	Alejandro Gonzalez Ochoa	Received

PB-0071	The impact of COVID-19 and venovenous ECMO on the generation and characteristics of extracellular vesicles	Ludwig Traby	Received

PB-74	Hyper-immunoglobulin- CovImmuneTM, provides a broader coverage against diverse SARS-CoV-2 variants relevant to the COVID-19 pandemic	Leon Rozen	Received

PB-0091	Fibrin monomers positivity during hospitalization is a good predictive marker of in-hospital mortality during COVID-19	David Smadja	Received

PB-0097	Intracellular nuclear proteins histone H3 and HMGB1 are predictive markers of disease severity and prognosis of COVID-19 patients	takayuki ikezoe	Received

PB-0104	Emergency Mobile and Point of Care Anticoagulation Clinic During (COVID-19) Curfew by Pharmacists in Saudi Arabia	Alayoubi Fakhr	Received

PB-0110	Comparison of D-dimer and fibrinogen levels in preCOVID-19 pandemic ICU patients and patients with severe COVID-19	Lisa Tingley	Received

PB-0130	High-throughput 384 well microplate factor activity assay	Leonid Parunov	Received

PB-0132	Hemostatic evaluation of patients with thrombocytopenia receiving platelet transfusion using the total thrombus formation analysis system (T-TAS)	RIVERA JOSE	Received

PB-0139	Heavy menstrual bleeding GWAS meta-analysis in 40,000 cases and 383,000 controls reveals 29 loci suggesting multiple contributing pathways of etiology	Jason Cunha	Received

PB-0152	The spectrum of FVIII-specific antibodies in persons with hemophilia A: a cross-sectional nationwide population study	Ilja Oomen	Received

PB-0157	In vitro thrombin generation in the presence of emicizumab sequence identical analogue (emi-SIA) and concizumab	Ellen McAllister	Received

PB-168	In vitro assessment of clinical coagulation assays in the presence of concizumab	Ellen McAllister	Received

PB-0173	Coagulation assay discrepancies for factor IX activity in hemophilia B	Hiroshi Inaba	Received

PB-0182	Development of a non-viral gene therapy approach for severe bleeding disorders	Brian Truong	Received

PB-0185	Immunologic Response to AAV Directed Expression of Enhanced Hemostatic Variant FVIII-QQ in Mice	Anna Sternberg	Received

PB-0188	Improved Quality of Life in People with Hemophilia A Following Gene Therapy with Dirloctocogene Samoparvovec (SPK-8011)	Margaret Ragni	Received

PB-0190	Structural, functional and carcinogenicity as essential liver biomarkers for gene therapy of hemophilia A	Oscar Segurado	Received

PB-191	myGTR: a patient engagement tool from the World Federation of Hemophilia Gene Therapy Registry	Mayss Naccache	Received

PB-0192	Novel Patient-directed Learning in the Era of Novel Therapies	Fiona Robinson	Received

PB-0204	Correlation Between the Clinical Phenotype and Genotype Profile in Children with Congenital Factor VII Deficiency	Rachel Kronenfeld	Received

PB-0208	Tittle: Spleen rupture in Afibrinogenemia: hemorrhagic or thrombotic	Claudia Djambas Khayat	Received

PB-0210	Heterozygous structural variation mimicking homozygous substitution in MCFD2 in a French patient with combined Factor V and Factor VIII deficiency.	Yohann JOURDY	Received

PB-0218	Trisomy X conferring moderate hemophilia A by extremely skewed X-chromosome inactivation	Keiko Shinozawa	Received

PB-219	Utility of ACMG classification to support interpretation of molecular genetic test results in patients with FVII deficiency	Rosa Sonja Alesci	Received

PB-0224	Effective management of surgical procedures of inherited FVII deficient patients 15 years experience at University Hospital in Ostrava	Radomira Hrdlickova	Received

PB-0226	Bleeding and clotting in the same patient: A case of Factor XI deficiency and thrombosis.	Maynolia Naidoo	Received

PB-227	Symptomatic Factor X Deficiency in a Single Family with a Genetic Mutation Previously Reported as of Uncertain Significance	Faryal Munir	Received

PB-0229	DESIGNING THE RYPLAZIM (PLASMINOGEN, HUMAN-tvmh) ARM OF ATHN TRANSENDS: SAFETY AND EFFECTIVENESS IN PEOPLE WITH PLASMINOGEN DEFICIENCY	Lynn Malec	Received

PB-0231	Liver Transplant Complicated by Reperfusion Injury in a Child with Severe Factor V Deficiency	Mehul Thakkar	Received

PB-0233	Von Willebrand disease in the east Mediterranean region: current situation and gaps	Claudia Khayat	Received

PB-236	Bleeding episode during a long-term anticoagulation with direct oral anticoagulant: an unusual revelation of a severe factor V deficiency	Laurie Goubeau	Received

PB-0243	Trends in Vitamin K antagonist use indicate prescription patterns that may be over-utilizing Direct Oral Anticoagulants without adequate gains in side effect profile or improved cost-effectiveness.	Cherian Verghese	Received

PB-0244	Analysis of Drug Related Problem associated with Direct Oral Anticoagulants: Findings from a medical records review by pharmacists in a large teaching hospital	Melissa Chow	Received

PB-0245	Equitable Care for Individuals with Inherited Bleeding and Substance Use and/or Mental Health Disorders	Jacqueline Bottacari	Received

PB-0246	FXIII Deficiency: A genetic diagnostic dilemma	Jodie Odame	Received

PB-0252	The role of hydroxychloroquine in the management of children with ITP and positive antinuclear antibodies	Oded Gilad	Received

PB-0256	The analysis of serum thrombopoietin levels in pediatric patients with acquired thrombocytopenic disorders	Zhenping Chen	Received

PB-0266	Effect of COVID-19 Vaccine or Infection on Pediatric Patients with Current or Prior Immune Thrombocytopenia	Wei Xuan Chue	Received

PB-0271	Acquired factor XI deficiency in a child with membranous glomerulonephritis	ANGELO MOLINARI	Received

PB-0290	Bleeding Complications in Children with Myeloproliferative Neoplasms and Thrombosis on Anticoagulation	Nicole Kucine	Received

PB-0301	Ocular Vein Occlusion in Pediatrics: Should Thrombophilia Investigation and Anticoagulant Treatment Be Initiated?	Sarina Levy-Mendelovich	Received

PB-0302	Preventing thrombosis in moderate-severe protein C deficiency: the effects of different treatment regimens in a boy with protein C level of 4 IU/dl.	Idske Kremer Hovinga	Received

PB-0304	Bivalirudin Anticoagulation for an Infant with Heparin Resistance on ECMO	Ge Zhang	Received

PB-0309	Safety and Efficacy of Apixaban Therapy in an Obese Adolescent with Pulmonary Embolism	Faryal Munir	Received

PB-312	Assessment of post-treatment anti-drug antibodies to caplacizumab in patients with immune-mediated thrombotic thrombocytopenic purpura	Carmen Evans	Received

PB-0314	Treatment Delay and outcomes in Elderly TTP Patients: A Nationwide Analysis	Amir Mahmoud	Received

PB-0323	Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta	Tammuella Chrisentery-Singleton	Received

PB-334	Immune-Mediated Thrombotic Thrombocytopenic Purpura Landscaping in Gulf Countries: A Real-World Evidence Study (ATHENA Study)	Carmen Evans	Received

PB-0336	Refractory Thrombotic Thrombocytopenic Purpura Treated by Discontinuation of Therapeutic Plasma Exchange	Tracey Cheves	Received

PB-0345	Diagnosing heparin-induced thrombocytopenia: A prospective multicentre study	Henning Nilius	Received

PB-0346	Monoclonal gammopathy of thrombotic/thrombocytopenic significance	Anand Padmanabhan	Received

PB-0355	Knock-in of homozygous NBEAL2 variants to model gray platelet syndrome in megakaryocytes derived from CRISPR-Cas9-edited pluripotent stem cells	Janine Collins	Received

PB-0357	Hereditary Thrombocytopenia with Platelet Sialic acid Deficiency and Mutations in the GNE genes	Tracey Cheves	Received

PB-0363	A case report of quinine-induced thrombotic microangiopathy treated with eculizumab	Philip Choi	Received

PB-0366	Ticagrelor Overdose Managed without Adverse Outcomes: Is Reversal Agent Necessary?	Tracey Cheves	Received

PB-0380	Corrections of Bernard Soulier Syndrome Megakaryocyte Phenotypes by Small Molecules and Interleukin-1a	Ponlapat Rojnuckarin	Received

PB-0419	The molecular basis of carrageenan-induced thrombosis involves platelet activation via C-type lectin like receptor 2 (CLEC-2)	Ryohei Yokomori	Received

PB-0423	Protein phosphatase 1 alpha from platelets dampen endotoxin -induced proinflammatory signaling and kidney tubular apoptosis and injury	K. Vinod Vijayan	Received

PB-0430	Treatment of APS patients with rivaroxaban or apixaban: A cohort single-center study.	Luis Rubalcava-Lara	Received

PB-0432	Identification of a Subset of Thrombotic Antiphospholipid Syndrome Patients with Significant Discordance in paired Capillary- and Venous- Monitoring with an International Normalized Ratio	Nuria Revilla	Received

PB-0437	Concordance of Phosphatidylserine/Prothrombin and APhL Antibodies Associated With Antiphospholipid Syndrome-Associated Pregnancy Morbidity	Laura Worfolk	Received

PB-0443	Innovative Non-isocyanate Polyurethane-derived Hemocompatible Polymers for Blood-contacting Medical Devices	Sofia Melo	Received

PB-0444	Residual pulmonary vascular obstruction is associated with prothrombotic fibrin clot phenotype in patients following pulmonary embolism	Anetta Undas	Received

PB-0445	Ultrasound shear wave elastography evaluation of acute deep vein thrombosis as a predictor for thrombus resolution	Damon Houghton	Received

PB-0449	Impact of self-reported race on Villalta Scale scores and correlation with venous disease specific quality of life: an exploratory analysis of the ATTRACT Trial	James Ching Shih	Received

PB-0450	Does Iliac Vein Stenting Reduce the Severity of Post-Thrombotic Syndrome? Progress on an Ongoing Multicenter Randomized Controlled Trial	Suresh Vedantham	Received

PB-0454	Incidence and predictors of portal vein thrombosis and mortality in patients with liver cirrhosis: a retrospective matched case-control two-centre study	Sadeem Aleid	Received

PB-0455	Bilateral asynchronous adrenal infarction in JAK2-positive essential thrombocythemia	Bobby Gouin	Received

PB-0460	Clinical effectiveness and safety of edoxaban in obese patients - Results of the Prospective DRESDEN NOAC REGISTRY (NCT01588119)	Jan Beyer-Westendorf	Received

PB-0464	Smaller nadroparin dose reductions required for patients with renal impairment: a multicenter study	Renate van Uden	Received

PB-0469	Frequency of INR monitoring and their impact on INR control during the COVID-19 pandemic	Tessa Elling	Received

PB-0474	Anticoagulant management and outcomes in non-traumatic intracranial hemorrhage complicated by venous thromboembolism	Sam Schulman	Received

PB-0477	Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension	Ilham Benzidia	Received

PB-0483	Enoxaparin for the long-term therapy of venous thromboembolism in patients with cancer and renal insufficiency. The RIETECAT-RI study.	Manuel Monreal	Received

PB-0485	Use of DOACs in the management of upper extremity deep venous thrombosis: a systematic review	Shiliang Ge	Received

PB-0486	Effect of Age on Risk for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis	Faizan Khan	Received

PB-0492	Review of edoxaban plasma concentrations from Kings College Hospital, UK	Rachel Clapham	Received

PB-0494	Defining the Optimal Cutoff Value of Gen-5 High-Sensitivity Troponin for the Risk-Stratification of Patients with Acute Pulmonary Embolism	Timothy Matthews	Received

PB-0498	Clinical outcomes of iliofemoral DVTs associated with May-Thurner Syndrome	Adrian Yeung	Received

PB-0502	Factors associated with outpatient treatment among patients with low-risk pulmonary embolism	Kyle Chang	Received

PB-0504	Clinical usefulness of risk tools predicting recurrence of unprovoked venous thromboembolism: a systematic review and meta-analysis	Karina Meijer	Received

PB-0505	Outcomes of patients with pulmonary embolism admitted to the Intensive Care Unit	Caroline Dix	Received

PB-0508	Direct oral anticoagulants for the treatment of venous thromboembolism in patients with -thalassemia: a multicenter analysis from the Extension-Myocardial Iron Overload in Thalassemia Network	Mariasanta Napolitano	Received

PB-0510	Primary Care Clinician Perceptions and use of Reduced-Dose Direct Oral Anticoagulants for Extended Phase Venous Thromboembolism Treatment	Scott Woller	Received

PB-0520	Atorvastatin treatment inhibits the procoagulant properties of a 3D culture model of the human neointimal layer	Alan Harper	Received

PB-0532	The Factor XIa Antibody Osocimab Combined with Enoxaparin Strongly Inhibits Clotting in Extracorporeal Circuits in vitro	Katarina Kovacevic	Received

PB-0538	A monoclonal antibody against human factor V impairs its activation and procoagulant function	Francis Ayombil	Received

PB-0541	Expression of recombinant human Factor VII activating protease (FSAP) and exploration of its 3D structure using AlphaFold.	Jonas Emsley	Received

PB-0542	Investigating thrombin-loaded fibrin in whole blood clot microfluidic assay via fluorogenic peptide.	Scott Diamond	Received

PB-0546	Effect of Atorvastatin on IL-6 and F12 in High Risk Thrombosis Patients with Cancer Undergoing Chemotherapy	Budi Setiawan	Received

PB-0562	Effects of high-fat and high-carbohydrate meals on coagulation and anticoagulation factors and lipid profile	Hiroko Tsuda	Received

PB-0584	Using heparin-calibrated assays to assess anti-factor Xa activity of factor Xa inhibitors (FXaI): a literature correlation analysis	Sarah Baker	Received

PB-0586	Protein S deficiency is Associated with an Increased Risk of Deep Vein Thrombosis in Pregnant Women Using Oral Contraceptive	Abdulrahman Algarni	Received

PB-0587	Identifying Variants of AAT M358R with Increased Selectivity for Plasma Kallikrein	Sangavi Sivananthan	Received

PB-0591	Alphafold AI based applications explored as tools for predicting contact proteins PK, FXI and HK structure and evolutionary relationships	jonas emsley	Received

PB-0593	Extending the Circulatory Half-life of an Engineered Kallikrein-Specific Inhibitor	Ghofran Al-Adimi	Received

PB-0600	Circulating platelet-derived extracellular vesicles are increased in severe COVID-19 disease	Tuukka Helin	Received

PB-609	Plasma Fractionation by HaemaFrac Technology - A Bioprocessing Innovation	Leon Rozen	Received

PB-0613	IL-6 dosage by ELISA tests in patients after COVID-19 infection: significant correlation between length of hospitalization and permanently altered levels of interleukin-6	Alessandra Prezotti	Received

PB-0616	UK National External Quality Assessment Scheme for Blood coagulation (UK NEQAS BC) evaluation of the point of care fibrinogen device	steve Kitchen	Received

PB-0621	: Emicizumab plasma concentrations are not related to bleeding rates using standard dosing, a call for dose adaptation	Kathelijn Fischer	Received

PB-0622	A Report of the Measurement of Steady State Emicizumab Levels in an Irish cohort of Persons with Severe Haemophilia A	Paula Grennan	Received

PB-0624	A-SURE: Intra-patient Comparison of Prophylactic Effectiveness of a Recombinant Factor VIII Fc Fusion Protein Versus Standard Half-life Factor VIII in Hemophilia A	Janeen Nuttall	Received

PB-0625	Emicizumab Prophylaxis in People with Hemophilia A Aged =50 Years with Comorbidities: Experience From the ATHN 7 Hemophilia Natural History Study	Helen Miller	Received

PB-0628	The World Federation of Hemophilia Living Guidelines Model	Mona Mayla	Received

PB-0629	Designing the Efanesoctocog Alfa Module of ATHN Transcends: Safety, Tolerability, and Effectiveness in Previously Untreated Patients with Hemophilia A	Lynn Malec	Received

PB-630	Final Analysis of Long-term Clinical Outcomes of Prophylaxis With a Recombinant Factor VIII Fc Fusion Protein in Adults Aged &8805;50 Years With Severe Hemophilia A	Doris Quon	Received

PB-0635	A usability study assessing handling and preference of the concizumab pen-injector in patients with haemophilia and caregivers	Ellen McAllister	Received

PB-0638	Final data from A-MOVE: 12-Month Prospective Multicentre Study to Investigate the Impact of Systematic Joint Examination on Treatment Management Decisions in Patients with Hemophilia A in France	Aurélien Lebreton	Received

PB-0639	Haemophilia; Ageing and Frailty	Susan Shapiro	Received

PB-0641	Association Between Physical Activity and Bleeding Events in People with Hemophilia A Receiving Emicizumab Prophylaxis: Interim Analysis of the TSUBASA Study	Helen Miller	Received

PB-0642	Determinants of the bleeding phenotype in persons with non-severe hemophilia	Samantha Gouw	Received

PB-0643	Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary	Andreas Roesch	Received

PB-0645	Evaluation of the Effect of Factor VIII on the Measurement of Emicizumab Levels in Plasma	Paula Grennan	Received

PB-0649	Results From the RESIST Study for Tolerance Induction in Patients With Poor Prognosis for ITI Success	Christoph Koenigs	Received

PB-650	Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Pediatric Patients with Hemophilia B: A review of results from Phase 3 trial studies	Bethany Phillips	Received

PB-0653	Can thrombin generation assays be used to guide the use of anticoagulants in people with haemophilia? an exploratory study	Caroline Dix	Received

PB-0654	Combined Point of Care Tools Improve Treatment Adherence and Health-Related Quality of Life in Patients with Hemophilia under regular prophylaxis: an Observational Mulicenter Prospective Study	Mariasanta Napolitano	Received

PB-661	Real-world Effectiveness and Safety of Damoctocog Alfa Pegol in Canadian Patients with Hemophilia A: Interim Results from the HEM-POWR Study	Bethany Lund-Yates	Received

PB-664	Treatment adherence in young people with hemophilia: perceptions of UK healthcare professionals	Bethany Phillips	Received

PB-669	Final Analysis of Long-term Clinical Outcomes of Recombinant Factor IX Fc Fusion Protein Prophylaxis in Adults &8805;50 Years With Severe Hemophilia B	Margaret Ragni	Received

PB-670	Nationwide survey on the care reality of people with mild hemophilia A and B in Germany - The Burden of mild Hemophilia	Rosa Sonja Alesci	Received

PB-672	Real-World data on patients with Hemophilia A switching to either BAY 94-9027 or BAY 81-8973 from Emicizumab using the ATHNdataset	Thomas Moulton	Received

PB-0679	Clinical Characteristics and Disease Outcomes in Previously Treated Patients with Haemophilia: Results from a Real-World Study in Europe and United States	Stevie Olsen	Received

PB-0684	Quality of life in patients & caregivers living with hemophilia A without inhibitors in spain, interim analysis of the HEMOLIFE study	Juan Luis Sanz	Received

PB-0685	A retrospective review of Heavy Menstrual Bleeding in women with inherent bleeding disorders a need for Joint Gynaecology-Haematology clinic	Bethan Myers	Received

PB-692	Matching-adjusted indirect comparison of rIX-FP versus rFIXFc for prophylactic treatment of hemophilia B	Bethany Phillips	Received

PB-0696	Management of bleeding in people with hemophilia A on prophylaxis with emicizumab in emergency situations: Recommendations from a Spanish expert panel	Laura Perez	Received

PB-697	To Test or Not to Test: Do all individuals with non-severe hemophilia A need DDAVP response testing?	Julia Hews-Girard	Received

PB-0719	Assessment of coagulation activation using thrombin generation assay in newly diagnosed acute myeloid leukemia	Noppacharn Uaprasert	Received

PB-0724	TF-FVIIa-PAR2--arrestin signaling regulates monocyte/macrophage responses to double stranded RNA	Kristin Grunz	Received

PB-0728	Models for in vitro investigation of Neutrophil activation	Joffrey Feriel	Received

PB-733	Patients with pancreatic cancer have a disturbed whole blood thrombin generation profile	Ruth Willems	Received

PB-0765	Increased complement C3a anaphylatoxin is associated with elevated factor VIII and altered fibrin clot properties in normotensive patients with acute pulmonary embolism	Anetta Undas	Received

PB-0775	Evaluation of Hemorrhage and Edema Expansion, Including Effect on Neutrophil-Mediated Neuroinflammation in Intracerebral Hemorrhage, Using Ir-CPI, a Thromboinflammation Inhibitor	Valérie Pireaux	Received

PB-0777	The Risk of Thrombosis in Patients with Acute Lymphoblastic Leukemia may be Explained by the Impact of Peripheral Blasts on Endothelial Cells: An In-vitro study	Anthony Chan	Received

PB-0787	Concordance of Low Molecular Weight and Unfractionated Heparin Serotonin Release Assays	Laura Worfolk	Received

PB-800	Infection with Ancestral SARS-CoV-2 versus Variants of Concern Delta and Omicron Differentially Alter the Megakaryocyte Transcriptome	Tessa Barrett	Received

PB-0804	Eculizumab use in the postpartum period for the treatment of pregnancy associated atypical hemolytic uremic syndrome: retrospective cohort study	Jose Santacruz	Received

PB-0808	Localized Endothelial Colony-Forming Cell-derived von Willebrand Factor (VWF) influences In Vivo Angiogenesis in VWF-deficient Mice	Mackenzie Bowman	Received

PB-0814	Endothelial cells, not blood, dictate where, when, and how hemostasis initiates under flow conditions: mechanistic studies using a vascularized hemostasis-on-a-chip system	Yumiko Sakurai	Received

PB-0825	Effect of von Willebrand factor concentrate on von Willebrand factor parameters during ECMO	Johannes Bösch	Received

PB-0827	WFH World Bleeding Disorders Registry Launches the First Global Data Collection on People with von Willebrand Disease	Ellia Tootoonchian	Received

PB-0829	Defining the Impact of Ageing on ISTH-BAT (ISTH-SSC endorsed Bleeding Assessment Tool) Scores in Women With Low von Willebrand Factor (VWF) Levels	Dearbhla Doherty	Received

PB-831	Novel VWF exon 9-10 duplication in a family with inherited bleeding, high VWF:Ag and FVIII levels, and loss of high molecular weight VWF multimers.	Jill Johnsen	Received

PB-0833	VWF Expression Mostly Confirms Genetic Prediction Algorithms in Type 1 VWD Variants	Sandra Haberichter	Received

PB-0837	Analysis of the change in diagnosis of von Willebrand disease by region and economic status	Ellia Tootoonchian	Received

PB-0838	Association Between Hemoglobin Values and VWF Assays: A Multi-Center Investigation	Jillian Simoneau	Received

PB-854	Could gynecologists contribute to an increased diagnosis of von Willebrand disease among women with heavy menstrual bleeding?	Bethany Phillips	Received

PB-0860	Von Willebrand factor is an independent predictor of short-term mortality in acutely ill patients with cirrhosis	Bente P. van den Boom	Received

PB-0863	Fatty acid oxidation fuels agonist-induced platelet activation and thrombus formation: Targeting beta-oxidation of fatty acids as an effective anti-platelet strategy	Paresh Kulkarni	Received

PB-0867	Alpha-2-macroglobulin precludes platelet aggregation in response to the Brain-Derived Neurotrophic Factor (BDNF)	Georges JOURDI	Received

PB-0872	MicroRNA-223-3p is a regulator of platelet procoagulant activity	Pierre Fontana	Received

PB-0875	A parallel kinetic Monte Carlo simulation of human stenotic thrombus growth with single platelet resolution from plaque rupture to occlusion	Kaushik Shankar	Received

PB-0880	The Brain-Derived Neurotrophic Factor (BDNF) sex-dependently affects platelet function in rats	Georges Jourdi	Received

PB-0894	Evaluating platelet function post transfusion with cold-stored vs room temperature platelets in patients with traumatic brain injury	Lara Hoteit	Received

PB-0906	Modified Platelet Storage Devices to Improve Quality During Storagee	Nicolas Pereyra	Received

PB-0918	Clinical Presentation and Outcomes of patients with cancer-associated isolated Distal Deep Vein Thrombosis	Jean philippe galanaud	Received

PB-0920	Mortality and Clinical Outcomes of Incidental versus Symptomatic Pulmonary Embolism Among Cancer Patients	Stephanie Young	Received

PB-0923	Treatment and outcomes of cancer-associated thrombosis, from traditional anticoagulation options to direct oral anticoagulants: a ten-year experience	Benjamin Jern Shern Wee	Received

PB-0927	Bleeding and thrombosis in patients receiving chimeric antigen receptor T-cell therapy	Sirui Ma	Received

PB-0934	The Safety and Efficacy of Direct Oral Anticoagulants (DOACs) Versus Low Molecular Weight Heparin (LMWH) in the Treatment of Thromboembolism (TE) in Patients with Hematological Malignancies	Doaa Attia	Received

PB-0935	TO INFORM OR NOT TO INFORM about cancer-associated thrombosis: A qualitative study on communication between healthcare professionals and patients with lung cancer	Anette Hjen	Received

PB-0940	Guideline Implementation Successes and Barriers to Prevent Cancer Associated Thrombosis in Community and Rural Cancer Clinics	Chris Holmes	Received

PB-0942	Prediction of Venous Thromboembolism in patients with cancer using Neural Network	Romy De Laat-Kremers	Received

PB-0943	Results of a clinical audit of intermediate dose low molecular weight heparin for thromboprophylaxis in newly diagnosed multiple myeloma patients	Karina Meijer	Received

PB-0945	Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism	Anders Dahm	Received

PB-0953	An Updated Systematic Review and Meta-Analysis of The Safety and Efficacy of Factor Xa Inhibitors Versus Low Molecular Weight Heparin Therapy for Treatment of Cancer Associated Venous Thromboembolism.	Rasana Albeirouti	Received

PB-0963	Clinical Outcomes of Anticoagulation for The Treatment of Thromboembolism (TE) in Elderly Cancer Patients	Doaa Attia	Received

PB-0977	Incidence and risk factors of venous and arterial thromboembolism in patients with advanced lung cancer under systemic treatment	Olga Morath	Received

PB-0986	Genotype-phenotype correlation in Belgian patients with inherited Protein C deficiency	Christelle Orlando	Received

PB-0988	Homozygous Protein S Deficiency in Siblings	Miguel Escobar	Received

PB-0990	Changes in thrombin generation parameters in newly diagnosed multiple myeloma patients in response to anti-myeloma therapy	Diego Velasco Rodríguez	Received

PB-0991	Clinical performance evaluation of a new Stago system for antithrombin levels determination: sthemO AT on sthemO 301	Véronique Le Cam Duchez	Received

PB-0995	Novel Thrombophilia - Prothrombin Belgrade Variant	Miguel Escobar	Received

PB-997	Utility of Thrombin Generation Assay for inherited thrombophilia screening	Joffrey Feriel	Received

PB-0998	Clinical performance evaluation of new Stago systems for protein S levels determination: sthemO PS Clot and sthemO PS Free on sthemO 301 analyzer	Véronique Le Cam Duchez	Received

PB-1004	Clinical performance evaluation of two new Stago systems for protein C levels determination: sthemO PC Clot and sthemO PC Chrom on sthemO 301 analyzer.	Véronique Le Cam Duchez	Received

PB-1006	Accuracy and interrater agreement of death event adjudications by physician trainees: Validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort	Caterina Marx	Received

PB-1014	The Optimal Cutoff of NT-proBNP for the Risk-Stratification of Hemodynamically Stable Patients with Acute Pulmonary Embolism	Timothy Matthews	Received

PB-1015	Venous Thromboembolism in Patients with Newly Diagnosed Lymphoma and its association with ThroLy and Khorana risk scores	Wan Awatif Wan Mohd Zohdi	Received

PB-1025	Evaluation of a new Stago system for D-dimer levels determination: sthemO DDi on sthemO 301	Véronique Le Cam Duchez	Received

PB-1031	Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study	Katelyn Sylvester	Received

PB-1032	Four-factor prothrombin complex concentrates for vitamin K antagonist reversal before urgent surgery: dosing and hemostatic efficacy in a double-blind randomized study	Sarah Baker	Received

PB-1038	Differences in clot formation and lysis between septic patients and controls assessed by whole-blood thromboelastometry: a prospective observational study	Ecaterina Scarlatescu	Received

PB-1039	Evaluation of External Quality Assessment material for activated clotting time on point of care devices: United Kingdom National External Quality Assessment Scheme for Blood Coagulation pilot studies.	Ian Jennings	Received

PB-1041	Evaluation of external quality assessment material on the renovated point of care device, United Kingdom National External Quality Assessment Scheme for Blood Coagulation studies.	Ian Jennings	Received

PB-1042	Impact of preoperative anticoagulation on perioperative bleeding in patients undergoing cardiopulmonary bypass for heart and lung transplantation	Kristine Schwietz	Received

PB-1046	Early Goal-directed Hemostatic Therapy (EGDHT) for Severe Acute Bleeding Management in the Intensive Care Unit	Tomaz Crochemore	Received

PB-1047	A patient with severe, refractory ITP and GI bleeding is kept hemodynamically stable over days with a combination therapy of tranexamic acid, recombinant FVIIa, F XIII and red blood cell concentrates	Wolfgang Korte	Received

PB-1051	Tyrosine Under-Sulfation of Factor VIII Results in T-Cell Response and Decreased Affinity Towards Thrombin in a Model System	Philip Olivares	Received

PB-1054	A Multi-Center, Stratification-Randomized , Double-Blind, Placebo-Controlled, Phase III Clinical Trial of Topical Recombinant Human Thrombin for Intraoperative Hemostasis	Jun Yu	Received

PB-1058	Mechanical properties of fibrin clots from patients with acute-on-chronic liver failure are inferior to those of healthy individuals and patients with sepsis without underlying liver disease	Ellen Driever	Received

PB-1060	Thrombin generation and fibrin clot structure in nephrotic patients with primary glomerular disorders	Thomas Mavrakanas	Received

PB-1062	Exogenous warfarin intoxication associated with Munchaüsen Syndrome	Alessandra Prezotti	Received

PB-1063	In vitro fibrinogen concentrate supplementation in patients with end-stage liver disease improves functional clot quality	Anna Tobiasch	Received

PB-1070	Small and large extracellular vesicles have different tissue factor activity in cancer, sepsis, and COVID-19	Ana Sachetto	Received

PB-1072	A Novel Factor VIII Specific APC Resistance Assay	Johnathan Morris	Received

PB-1076	Congenital protein C deficiency is associated with prothrombotic plasma fibrin clot phenotype	Anetta Undas	Received

PB-1077	A novel C238G, PROC mutation in patients with thromboembolism, causes intracellular protein retention	Pansakorn Tanratana	Received

PB-1081	Identification of related molecular biological effects on two novel point mutations in inherited antithrombin deficiency	Shiue-Wei Lai	Received

PB-1088	The effect of DOAC-Stop on lupus anticoagulant testing in plasma patients receiving direct oral anticoagulant	Anetta Undas	Received

PB-1090	Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa inhibitor-associated bleeding	Ineke Muir	Received

PB-1102	Evaluation of the ability of commercial ELISAs to measure tissue factor in human plasma	Ana Sachetto	Received

PB-1103	Clinical performance evaluation of the new Stago systems for APTT determination: sthemO PTTA and sthemO CK Prest on sthemO 301 analyzer.	Joffrey Feriel	Received

PB-1105	Post-infusion monitoring of Afstyla FVIII replacement therapy data from the UK National External Quality assessment for Blood Coagulation (UK NEQAS BC) programme 2022.	Anna Williams	Received

PB-1110	Implementation of International Society on Thrombosis and Haemostasis definitions of major and clinically relevant non-major bleed events in electronic health records	Adeline Kam	Received

PB-1112	UK National External Quality Assessment Scheme for Blood Coagulation (UK NEQAS BC) Emicizumab programme, survey July 2022 results for modified one-stage assay and chromogenic assay.	Christopher Reilly-Stitt	Received

PB-1115	Open-label, Method Comparison Study to Assess the Onset of Aspirin Effects with 162mg and 650mg Doses by VerifyNow Assay	Kevin Bliden	Received

PB-1116	Applications of DOAC removal in the Laboratory	Sunny Jamati	Received

PB-1121	Laboratory INRs determined with commercial thromboplastins in 450 centres before and after the establishment of the IRP for human thromboplastin - rTF 16 : Data from UK NEQAS for Blood Coagulation	steve kitchen	Received

PB-1122	Limits on the correction of inner filter effect and substrate consumption by the calibrated automated thrombinography algorithm: an edge of failure study	Mikhail Ovanesov	Received

PB-1123	Measurement of activated factor X based on complex formation with tissue factor pathway inhibitor	Alfred Weber	Received

PB-1129	Analytical Performances Evaluation of the Thrombophilia Hemostasis Test Panel on sthemO 301 Analyzer	Emilie Frisan	Received

PB-1130	Anticoagulant activity of factor Xa-inhibiting DOACs is increased synergistically by dabigatran and argatroban	Tom Exner	Received

PB-1131	Clinical performance evaluation of the new Stago system for prothrombin time determination: sthemO PT assay on sthemO 301 analyzer	Joffrey Feriel	Received

PB-1132	Comparison of thrombophilia assay results for the ISTH/SSC Plasma Standard from different EQA providers data from the EQATH group	Ian Jennings	Received

PB-1133	DaXa, a non-calibrated anti-FXa assay that can be used to rapidly quantify DOAC concentration in acute medical emergencies.	L. van Pelt	Received

PB-1134	Determination and verification of reference intervals on the automated coagulation analyzer sthemO 301	Romy de Laat-Kremers	Received

PB-1135	Evaluation of charcoal based direct oral anticoagulant (DOAC) neutralisation in the laboratory measurement of lupus anticoagulant (LA)	Hazel Medforth	Received

PB-1140	Laboratory features and genotype of a family with heritable dysfibrinogenaemia (HD)	GLORIA GARCIA-DONAS	Received

PB-1143	Analytical Performance Evaluation of a New Stago System SthemO 201	Romy de Laat-Kremers	Received

PB-1148	Frozen plasmas can replace fresh plasmas in ISI calibrations for secondary thromboplastin standards for multiple reagent/instrument combinations	Matthew Kitchen	Received

PB-1149	International Normalised Ratio measurement during bridging with Low Molecular Weight Heparin	An Stroobants	Received

PB-1154	Temporary isolated reagent-specific gross prolongation of APTT can be caused by acidosis	Anne Sermon-Cadd	Received

PB-1155	Analytical Performances Evaluation of the sthemO DDi M Assay on the sthemO 301 Analyzer	Emilie Frisan	Received

PB-1156	Clinical performance evaluation of the new Stago system for fibrinogen and thrombin time determination: sthemO Fib and sthemO Thrombin on sthemO 301 analyzer	Joffrey Feriel	Received

PB-1157	Comparison of (semi-)automated thrombin generation platforms for specific coagulopathies with bleeding diathesis.	Sanna Rijpma	Received

PB-1160	Detection of drug-induced platelet inhibition with sonic estimation of elasticity via resonance using the QuantraTM: an observational in-vitro study with healthy volunteers	Jan Krumeich	Received

PB-1161	Evaluation of three Prothrombin Time reagents and their sensitivity to extrinsic pathway factor deficiencies (FII, FV and FVII)	Emmanuelle Jeanpierre	Received

PB-1162	Precision Performances Evaluation of sthemO Routine Tests on sthemO 301 Analyzer	Emilie Frisan	Received

PB-1166	The true effect of haemolysis interference on routine coagulation tests using paired matched samples performed on the Sysmex CN-series coagulation analyser	George Tarpley	Received

PB-1170	Evaluation of the Analytical Performance of an Automated von Willebrand Factor GPIbM Activity Assay	Laura Worfolk	Received

PB-1174	Effect of hemolysis on coagulation tests as performed on HORIBA Medical Yumizen G1550 Analyser. How HIL auto-check can help.	Kevin Horner	Received

PB-1176	Analytical Performances Evaluation of the sthemO VWF:Ag Assay on the sthemO 301 Analyzer	Emilie Frisan	Received

PB-1179	Evaluation of the point-of-care H10 Hemcheck device to detect haemolysis in whole blood.	Lee Beckett	Received

PB-1180	The differences and correlations of LTA results obtained using different sampling methods.	Petr Kessler	Received

PB-1187	High plasma dabigatran levels causing falsely low fibrinogen results: a report of two cases	Sara Ng	Received

PB-1190	Evaluation of Anti-Xa assay for monitoring Low Molecular Weight Heparin (LMWH) using dedicated Stago reagent and analyser	Vishnu Prasad	Received

PB-1211	Individual determination of the components of the fibrinolytic system in platelet-depleted plasma and derived euglobulin fraction	Marion Bareille	Received

PB-1213	The Development of a Mini-scale Euglobulin Clot Lysis Assay	Steven Bruzek	Received

PB-1219	Structure-function studies on the serine protease domain of Factor VII activating protease (FSAP) to characterize its interaction with substrates and inhibitors.	Jonas Emsley	Received

PB-1226	Acquired haemophilia A in Finland: a nationwide study of incidence, treatment and outcomes	Vuokko Nummi	Received

PB-1227	Lupus anticoagulant in acquired hemophilia A subjects in Quebec: data from the Quebec Reference Center for Inhibitors	Clémence Merlen	Received

PB-1228	Inhibitor detection in acquired hemophilia A: a comparison between the Nijmegen modified Bethesda assay and an anti-FVIII ELISA	Marie-Astrid van Dievoet	Received

PB-1229	Haemostatic control with recombinant porcine factor VIII in acquired haemophilia A	Anna Buczma	Received

PB-1237	Validation of a semi-automated Von Willebrand Multimer assay for use in VWD classification	Mairead Doyle	Received

PB-1241	ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation	Margaret Ragni	Received

PB-1243	Comparison of Quality of Life and Bleeding Phenotypes in People with Congenital Hemophilia A: Longitudinal Study from the PicnicHealth Database of PROMIS-29 v2.0 scores	Miller Helen	Received

PB-1245	Efficacy, safety and dosing of pasteurized plasma-derived von Willebrand factor/Factor VIII concentrate for the treatment of von Willebrand Disease: a systematic review	Bethany Phillips	Received

PB-1249	Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents With Severe Hemophilia A	Pratima Chowdary	Received

PB-1250	Quality of Life in Females and Males with Mild Congenital Hemophilia A: A Longitudinal Study from the PicnicHealth Database of PROMIS-29 v2.0 Scores	Helen Miller	Received

PB-1251	The use of extended half-life factor IX products in the surgical setting a UK hemophilia center experience	Bethany Phillips	Received

PB-1252	Value of Hemophilia Drug Treatment Using Analysis of the Area Under the Curve	Bethany Lund-Yates	Received

PB-1254	A New Tool to Assist in Treatment Selection The World Federation of Hemophilia (WFH) Shared Decision-Making (SDM) Tool	Julia Chadwick	Received

PB-1255	An update on real-world use of rVIII-SingleChain in patients with haemophilia A in Germany: Interim results from a prospective, non-interventional study	Bethany Phillips	Received

PB-1256	Complication Analysis in Korean Patients with Hemophilia A from 2007 to 2019: A Nationwide Study by the Health Insurance Review and Assessment Service Database	Ye Jee Shim	Received

PB-1263	Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study	Bethany Lund-Yates	Received

PB-1273	Inhibitor Recurrence on Emicizumab Prophylaxis in Tolerized Patients with Severe Hemophilia A	Sonata Saulyte Trakymiene	Received

PB-1278	Real-World data on patients with Hemophilia A with previous inhibitors switching to either BAY 94-9027 or BAY 81-8973 in the ATHNdataset	Thomas Moulton	Received

PB-1282	Real-World Unmet Needs Of Adult Patients With Severe Hemophilia A Without Inhibitors In Poland: How To Select The Optimal Therapy?	Wojciech Giza	Received

PB-1290	Successful very low dose immune tolerance induction with albutrepenonacog alfa in a severe hemophilia B child with anaphylactic reaction to factor IX	Francisco Jose Lopez Jaime	Received

PB-1291	Joint range of motion findings among female patients with hemophilia A from the ATHNdataset	Thomas Moulton	Received

PB-1292	Rationale and Design of pathfinderReal: A Prospective, Non-Interventional Study Assessing Joint Health in Adults With Haemophilia A After Switching to Prophylaxis With Turoctocog Alpha Pegol (N8-GP)	Ellen McAllister	Received

PB-1296	A prospective, non-interventional study to investigate the effectiveness of rVIII-SingleChain in patients with hemophilia A	Bethany Phillips	Received

PB-1299	Obstetrical decision-making in moderate or severe hemophilia A and B: a qualitative study exploring parents experiences, preferences and needs	Shannon Lane	Received

PB-1301	Low-titer inhibitor and decreased FVIII activity to 1.1 with increased bleeding in a 4 year old patient with congenital mild hemophilia A	Ivonne Wieland	Received

PB-1303	A study of support for hemophilia patients using the Questionnaire for daily movement and sensory of PwH	AYA NAKAO	Received

PB-1309	Switching from Factor VIIa to Emicizumab in Patients with Hemophilia A and Inhibitor (HAI) in Korea	Sugi Jeon	Received

PB-1311	Prophylactic Efficacy Of VGA039, An Anti-Protein S Monoclonal Antibody, In A Novel Non-Human Primate Model Of Acquired Von Willebrand Disease	Benjamin Kim	Received

PB-1313	Factor V as adjunct to fibrinogen and prothrombin complex concentrate in an in vitro model of combined severe trauma-induced coagulopathy and rivaroxaban anticoagulation	Herm-Jan Brinkman	Received

PB-1314	Risk Assessing Medical Inpatients for Bleeding Events: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study	Hanny Al-Samkari	Received

PB-1315	Weight-band dosing with Mim8: using modelling to support a streamlined approach to haemophilia A treatment	Luke Hounslow	Received

PB-1317	Assessment of the Combined Effects of Emicizumab and Fitusiran with in vitro Spiking of Emicizumab and Simulated Fitusiran into Factor VIII Deficient Plasma using Thrombin Generation Assay	Sibgha Zaheer	Received

PB-1325	A novel recombinant factor VII D60A may potentially reduce the risk of thrombotic complications	Karnsasin Seanoon	Received

PB-1329	Retrospective Study of the Effectiveness and Safety of the Use of rIX-FP in Patients with Haemophilia B. Experience of four centres in the Region of Castilla y León.	Elena Maria Fernandez Fontecha	Received

PB-1341	Obinutuzumab-induced thrombocytopenia: an under-recognized immunotherapy related thrombocytopenia	Philip Choi	Received

PB-1349	Clinical relevance and management of bleeding in patients with myelodysplastic syndromes and severe thrombotytopenia: a retrospective analysis	Mariasanta Napolitano	Received

PB-1352	A Survey on anticoagulation in Patient with ITP	Rosa Sonja Alesci	Received

PB-1355	Long vaccine-induced immune thrombotic thrombocytopenia: a case report	Guillaume Roberge	Received

PB-1360	High annualized bleeding rates in pediatric patients with mild inherited platelet function defects (IPFD)	Shelly Saini	Received

PB-1362	Fibrinogen contribution to clot strength in septic patients with hematologic malignancies and thrombocytopenia	Tomaz Crochemore	Received

PB-1368	Platelet subpopulations in decompensated cirrhotic children.	Marie-Astrid van Dievoet	Received

PB-1369	Relevance of the Absence of Integrin aIIb expression by Flow Cytometry in Acquired Glanzmanns Thrombasthenia	Nuria Revilla	Received

PB-1382	Inherited platelet function disorder in pediatric patient with identified CalDAG-GEFI deficiency	Eduardo Morín	Received

PB-1383	RUNX1-mutated familial platelet disorder (RUNX1-FPD) with associated acute myeloid leukaemia a case/family series	Luke Attwell	Received

PB-1384	Survey on Functional and Molecular Characterization of Inherited Platelet Disorders in Spain	JOSE RIVERA	Received

PB-1388	Sticky platelet syndrome: clinical experience from a tertiary center	Ramiro José Núñez Vázquez	Received

PB-1396	Successful hip replacements in a Glanzmann thrombasthenia patient with anti-platelet antibodies and platelet- refractory disease using rFVIIa: a case report	Karla Rener	Received

PB-1416	Challenge in the investigation of patients with bleeding: Delayed diagnosis of Vascular Ehlers-Danlos Syndrome	Alessandra Nunes Prezotti	Received

PB-1436	Deletion of PAR1 in iPSCs-derived Vascular Smooth Muscle Cells results in increased Tissue Factor-dependent Thrombin Generation	Anxhela Habibi	Received

PB-1441	The risk of recurrent venous thromboembolism of patients with homozygous or double heterozygous factor V Leiden and/or prothrombin G20210A mutation: a prospective cohort study	Lisbeth Eischer	Received

PB-1443	Detection of genetic chimerism for thrombogenic variants in a liver transplant patient.	Jose Luis Rubio-Prieto	Received

PB-1448	Genetic polymorphisms in varicose veins with and without thrombosis	Jana Hirmerova	Received

PB-1452	Hemorrhagic and thrombotic complications in patients receiving therapeutic plasma exchange	Sirui Ma	Received

PB-1456	The Impact of Heart Rate on the Prediction of Mortality in Patients with Acute Pulmonary Embolism	Kwadwo Osei Bonsu	Received

PB-1458	Thromboembolic (TE) Events in Cold Agglutinin Disease (CAD): Post-hoc Analysis PRE- and ON-sutimlimab Treatment in the Phase 3 CARDINAL and CADENZA Studies	Ronnie Yoo	Received

PB-1460	Venous anomalies an under-recognised but important cause of venous thromboembolism (VTE)	Joanne So	Received

PB-1461	Peri-operative Venous Thromboembolism (VTE) Risk for Below Knee Amputations	KHANH NGUYEN	Received

PB-1462	The Safety of Anticoagulation in Electroconvulsive Therapy A Systematic Review	Lan Deng	Received

PB-1464	Health Literacy among anticoagulated patients from a specialized unit and its impact on treatment.	Maria Guillermo Esposito	Received

PB-1467	Hospital-acquired (HA) versus post-discharge (PD) venous thromboembolism (VTE) similarities and differences: Analysis of the Medical Inpatient Thrombosis and Hemostasis (MITH) population	Mansour Gergi	Received

PB-1474	Analysis of Thromboprophylaxis Prescribing Using a Cohort Extraction and Information Retrieval Platform, a UK Experience	Rachel Clapham	Received

PB-1477	An Early Coagulation Factor Dominant Hypercoagulability is Followed by a Prolonged Platelet-Dominant Hypercoagulability in Patients with Hip Fracture	Jessica Duong	Received

PB-1478	Attributes of Randomized Controlled Trials and Their Associations With Funding Sources in Venous Thromboembolism Prophylaxis for Patients With Cancer: A Bibliographical Analysis	Lucy Zhao	Received

PB-1481	Evaluation of the usage of an electronic venous thromboembolism assessment tool for ambulatory oncology patients at a Canadian community cancer centre	Anjali Sachdeva	Received

PB-1485	Patients knowledge about venous thromboembolism and oral anticoagulation increases the risk of clinical outcomes during long-term follow-up	Aleksandra Golab	Received

PB-1488	Risk of venous thromboembolic disease and adequacy of thromboprophylaxis at a teaching hospital and incidence of VTE in the three months after admission	Ana Pizzarossa	Received

PB-1491	Prevention of venous thromboembolism after thermal methods of treatment of lower extremity varicose vein disease	Oleg Atamanyuk	Received

PB-1497	Patients Prefer Oral Agents Over Subcutaneous Injections for Thromboprophylaxis Following Hip Fracture Surgery	Jessica Duong	Received

PB-1498	Risk of venous thromboembolic disease and adequacy of prophylaxis in hospitalized cancer patients in Uruguay	Ana Pizzarossa	Received

PB-1509	Antiphosphatidylserine/prothrombin antibodies in obstetric antiphospholipid syndrome: a case-control study	Arne Vandevelde	Received

PB-1512	Antithrombin Concentrate Supplementation and Incidence of Coagulation Events in Pregnant Women Tested for Antithrombin Levels: Results from a Real-World Electronic Health Record (EHR) Database	Andra James	Received

PB-1517	Effect of uteroplacental manipulation on hemostatic markers during cesarean delivery and hysterectomy for placenta accreta spectrum	Jun Teruya	Received

PB-1523	Inter-expert algorithms agreement to diagnose thrombotic microangiopathies in pregnancy	Jose Rojas	Received

PB-1524	Preferences of pregnant women for postpartum thromboprophylaxis: the bicentric PREFER-PP study	Marc Blondon	Received

PB-1525	Healthcare Resource Utilization in Pregnant Women with Suspected Antithrombin Deficiency: Results from a Nationwide Hospital Chargemaster Database	Andra James	Received

PB-1531	Management and outcomes of pregnancy and childbirth in known and unknown haemophilia carriers: a retrospective analysis from a reference Center in Italy.	Mariasanta Napolitano	Received

PB-1537	Changes in whole blood platelet aggregation and clotting parameters during pregnancy and postpartum in women with and without heterozygous Factor V Leiden mutation	Margunn Tsdal	Received

PB-1538	Pregnancy Outcomes in Women with Sickle Cell Trait	Sarah Sewaralthahab	Received

PB-1545	Antiphospholipid antibodies profile in women with periodontal disease	Patricia Casais	Received

ISTH 2023 Congress

June, 24-28 Montreal

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 24/06/2023 TO 24/06/2023

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access